Drug intelligence / Profile preview

cannabidiol + tetrahydrocannabinol + cannabidivarin

Development stage
Unknown
Lead developer
Jazz Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Oromucosal, Inhalation
01

Overview

A combination of three natural cannabinoids derived from Cannabis sativa: **cannabidiol (CBD)**, **tetrahydrocannabinol (THC)**, and **cannabidivarin (CBDV)**. Each component acts on the endocannabinoid system with both overlapping and distinct mechanisms. - **THC** is a partial agonist at cannabinoid CB1 and CB2 receptors, producing psychoactive and analgesic effects. - **CBD** is a negative allosteric modulator at the CB1 receptor and modulates several other targets, contributing to anticonvulsant, anxiolytic, and anti-inflammatory effects. - **CBDV**, a non-psychoactive homolog of CBD, may modulate neuronal excitability and has shown potential anticonvulsant effects. Recent laboratory studies indicate that **CBDV may counteract or reverse some THC+CBD effects on neuronal firing, suggesting unique neuroregulatory properties**[1][2][4]. This combination has not been approved as a standardized commercial medicinal product but mirrors "full spectrum" cannabinoid extracts under investigation for various neurological and pain indications[2][3].

02

Targets

GLRA3 (Glycine receptor alpha-3 subunit)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))TRPV2 (Transient receptor potential cation channel subfamily V member 2)TRPV1 (Transient receptor potential cation channel subfamily V member 1)CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)TRPA1 (Transient receptor potential cation channel subfamily A member 1)FAAH

Beyond the preview

Go deeper on cannabidiol + tetrahydrocannabinol + cannabidivarin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cannabidiol + tetrahydrocannabinol + cannabidivarin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call